Candel Therapeutics Investor Relations Material

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer treatment. The company’s approach involves using genetically modified viruses to induce immunogenic cell death in cancer cells, which unmask tumor antigens within an activated microenvironment. This process triggers a systemic and durable immune response against tumors, acting as an in situ vaccination. Candel’s therapies are designed to potentially improve survival rates and maintain the quality of life for patients across various stages of cancer. The company is headquartered in Needham, Massachusetts, and its shares are listed on NASDAQ.